Immuron Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMRN research report →
About the company
Immuron Limited is a biopharmaceutical company focused on the discovery, development, and global commercialization of polyclonal antibodies, with operations spanning Australia, the United States, and other international markets. The company's activities are structured into two key segments: Research and Development, and Hyperimmune Products. Currently, Immuron markets two key products.
- CEO
- Steven George Lydeamore
- IPO
- 2017
- Employees
- 7
- HQ
- Carlton, VIC, AU
Price Chart
- Market Cap
- $7.09M
- P/E
- -1.93
- P/S
- 1.24
- P/B
- 0.75
- EV/EBITDA
- 0.14
- Div Yield
- 0.00%
- Gross Margin
- 63.69%
- Op Margin
- -68.38%
- Net Margin
- -62.14%
- ROE
- -43.95%
- ROIC
- -29.04%
- Revenue
- $7.29M · 48.63%
- Net Income
- $-5,215,987 · 24.81%
- EPS
- $-0.90 · 25.66%
- Op Income
- $-5,344,548
- FCF YoY
- -4.36%
- 52W High
- $2.39
- 52W Low
- $0.68
- 50D MA
- $1.04
- 200D MA
- $1.20
- Beta
- 0.49
- Avg Volume
- 241.89K
Get TickerSpark's AI analysis on IMRN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Palumbo Flavio | other | 0 |
| Oct 24, 24 | Palumbo Flavio | other | 640,824 |
| Mar 18, 26 | Pollock Daniel Jude | other | 0 |
| Mar 18, 26 | Pollock Daniel Jude | other | 0 |
| Dec 8, 25 | Pollock Daniel Jude | other | 333,333 |
| Nov 24, 25 | Pollock Daniel Jude | other | 1,000,000 |
| Nov 24, 24 | Brennan Paul Gerard | other | 666,667 |
| Nov 24, 25 | Brennan Paul Gerard | other | 1,000,000 |
| Mar 18, 26 | Kanellos Jerry | other | 0 |
| Oct 24, 24 | Kanellos Jerry | other | 272,134 |
Our IMRN coverage
Recent articles, reports, and earnings notes.
No research on IMRN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IMRN report →Similar companies
Peers in the same neighborhood.